SCHEMBL1713059

SCHEMBL1713059

COc1ccc(Cl)cc1S(=O)(=O)N1CCCC(C(=O)N2CCCCC2c2ccccc2)C1

nearest known ligand 0.62

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.62
KMT2A Q03164 5/20 0.56
MEN1 O00255 4/20 0.56
POLB P06746 5/20 0.55
KDM4E B2RXH2 2/20 0.54
ALDH1A1 P00352 2/20 0.54
HPGD P15428 1/20 0.54
RAB9A P51151 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.50
TDP1 Q9NUW8 1/20 0.49
HTT P42858 2/20 0.49
GAA P10253 1/20 0.47
CNR1 P21554 1/20 0.47
TP53 P04637 1/20 0.46
TSHR P16473 1/20 0.46
MAPK1 P28482 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1713131 0.98 ATM (0.64) ATMKMT2AMEN1POLBKDM4E
SCHEMBL4095724 0.96 ATM (0.61) ATMKMT2AMEN1POLBKDM4E
SCHEMBL1712984 0.89 KMT2A (0.54) ATMKMT2AMEN1POLBKDM4E
SCHEMBL1712578 0.87 POLB (0.54) ATMKMT2AMEN1POLBKDM4E
SCHEMBL3428003 0.85 ATM (0.51) ATMKMT2AMEN1POLBKDM4E
SCHEMBL1722857 0.83 CNR1 (0.56) KMT2AMEN1POLBKDM4EALDH1A1
SCHEMBL1713376 0.82 LMNA (0.55) KMT2AMEN1POLBALDH1A1HPGD
SCHEMBL1713030 0.81 CNR1 (0.56) KMT2AMEN1POLBKDM4EALDH1A1
SCHEMBL1712872 0.80 AKR1C3 (0.55) KMT2AMEN1POLBALDH1A1HPGD
SCHEMBL7832350 0.80 ALDH1A1 (0.53) KMT2AMEN1POLBALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130217729-A1 PIPERIDINE SULPHONAMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2013-08-22 US claimed
US-20120238602-A1 PIPERIDINE SULPHONAMIDE DERIVATIVES KNUST HENNER (DE) 2012-09-20 US claimed
EP-2252587-B1 PIPERIDINE SULFONAMIDE DERIVATIVES HOFFMANN LA ROCHE (CH) 2011-07-20 EP claimed
US-20090203736-A1 PIPERIDINE SULPHONAMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-08-13 US claimed
US-8691846-B2 Piperidine sulphonamide derivatives HOFFMANN-LA ROCHE INC. (US) 2014-04-08 US disclosed
US-8691846-B2 Piperidine sulphonamide derivatives HOFFMANN-LA ROCHE INC. (US) 2014-04-08 US disclosed
US-20130217729-A1 PIPERIDINE SULPHONAMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2013-08-22 US disclosed
US-20130217729-A1 PIPERIDINE SULPHONAMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2013-08-22 US disclosed
US-20130217729-A1 PIPERIDINE SULPHONAMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2013-08-22 US disclosed
US-20120238602-A1 PIPERIDINE SULPHONAMIDE DERIVATIVES KNUST HENNER (DE) 2012-09-20 US disclosed
US-20120238602-A1 PIPERIDINE SULPHONAMIDE DERIVATIVES KNUST HENNER (DE) 2012-09-20 US disclosed
US-20120238602-A1 PIPERIDINE SULPHONAMIDE DERIVATIVES KNUST HENNER (DE) 2012-09-20 US disclosed
EP-2252587-B1 PIPERIDINE SULFONAMIDE DERIVATIVES HOFFMANN LA ROCHE (CH) 2011-07-20 EP disclosed
EP-2252587-B1 PIPERIDINE SULFONAMIDE DERIVATIVES HOFFMANN LA ROCHE (CH) 2011-07-20 EP disclosed
EP-2252587-A1 PIPERIDINE SULFONAMIDE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2010-11-24 EP disclosed
WO-2009100994-A1 PIPERIDINE SULFONAMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-08-20 WO disclosed
WO-2009100994-A1 PIPERIDINE SULFONAMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-08-20 WO disclosed
US-20090203736-A1 PIPERIDINE SULPHONAMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-08-13 US disclosed
US-20090203736-A1 PIPERIDINE SULPHONAMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-08-13 US disclosed
US-20090203736-A1 PIPERIDINE SULPHONAMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-08-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203736-A1 PIPERIDINE SULPHONAMIDE DERIVATIVES HCRTR2, PER2, HCRTR1 ATM 2276/4885KMT2A 201/4885MEN1 2182/4885
US-20120238602-A1 PIPERIDINE SULPHONAMIDE DERIVATIVES HCRTR2, PER2, HCRTR1 ATM 2276/4885KMT2A 201/4885MEN1 2182/4885
US-20130217729-A1 PIPERIDINE SULPHONAMIDE DERIVATIVES HCRTR2, PER2, HCRTR1 ATM 2276/4885KMT2A 201/4885MEN1 2182/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.